Skip to main content
SpringerLink
Log in

New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma

  • Insight
  • Published:
Science China Life Sciences Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Bi, K., He, M.X., Bakouny, Z., Kanodia, A., Napolitano, S., Wu, J., Grimaldi, G., Braun, D.A., Cuoco, M.S., Mayorga, A., et al. (2021). Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma. Cancer Cell 39, 649–661.e5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Braun, D.A., Bakouny, Z., Hirsch, L., Flippot, R., Van Allen, E.M., Wu, C. J., and Choueiri, T.K. (2021). Beyond conventional immune-checkpoint inhibition—novel immunotherapies for renal cell carcinoma. Nat Rev Clin Oncol 18, 199–214.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Curigliano, G., Gelderblom, H., Mach, N., Doi, T., Tai, D., Forde, P.M., Sarantopoulos, J., Bedard, P.L., Lin, C.C., Hodi, F.S., et al. (2021). Phase I/Ib clinical trial of sabatolimab, an anti-TIM-3 antibody, alone and in combination with spartalizumab, an anti-PD-1 antibody, in advanced solid tumors. Clin Cancer Res 27, 3620–3629.

    Article  CAS  PubMed  Google Scholar 

  • Diab, A., Hamid, O., Thompson, J.A., Ros, W., Eskens, F.A.L.M., Doi, T., Hu-Lieskovan, S., Klempner, S.J., Ganguly, B., Fleener, C., et al. (2022). A phase I, open-label, dose-escalation study of the OX40 agonist ivuxolimab in patients with locally advanced or metastatic cancers. Clin Cancer Res 28, 71–83.

    Article  CAS  PubMed  Google Scholar 

  • Krishna, C., DiNatale, R.G., Kuo, F., Srivastava, R.M., Vuong, L., Chowell, D., Gupta, S., Vanderbilt, C., Purohit, T.A., Liu, M., et al. (2021). Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy. Cancer Cell 39, 662–677.e6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Meric-Bernstam, F., Larkin, J., Tabernero, J., and Bonini, C. (2021). Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet 397, 1010–1022.

    Article  CAS  PubMed  Google Scholar 

  • Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022). A natural polyphenol exerts antitumor activity and circumvents anti-PD-1 resistance through effects on the gut microbiota. Cancer Discovery 12, 1070–1087.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Morad, G., Helmink, B.A., Sharma, P., and Wargo, J.A. (2022). Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell 185, 576.

    Article  CAS  PubMed  Google Scholar 

  • Motzer, R.J., Jonasch, E., Agarwal, N., Alva, A., Baine, M., Beckermann, K., Carlo, M.I., Choueiri, T.K., Costello, B.A., Derweesh, I.H., et al. (2022). Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Comprehensive Cancer Network 20, 71–90.

    Article  Google Scholar 

  • Schöffski, P., Tan, D.S.W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R.D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., et al. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. J Immunother Cancer 10, e003776.

    Article  PubMed  PubMed Central  Google Scholar 

  • Segal, N.H., He, A.R., Doi, T., Levy, R., Bhatia, S., Pishvaian, M.J., Cesari, R., Chen, Y., Davis, C.B., Huang, B., et al. (2018). Phase I study of single-agent utomilumab (PF-05082566), a 4-1BB/CD137 agonist, in patients with advanced cancer. Clin Cancer Res 24, 1816–1823.

    Article  CAS  PubMed  Google Scholar 

  • Tang, X.Y., Shi, A.P., Xiong, Y.L., Zheng, K.F., Liu, Y.J., Shi, X.G., Jiang, T., and Zhao, J.B. (2021). Clinical research on the mechanisms underlying immune checkpoints and tumor metastasis. Front Oncol 11, 693321.

    Article  PubMed  PubMed Central  Google Scholar 

  • Xia, L., Tian, E., Yu, M., Liu, C., Shen, L., Huang, Y., Wu, Z., Tian, J., Yu, K., Wang, Y., et al. (2022). RORγt agonist enhances anti-PD-1 therapy by promoting monocyte-derived dendritic cells through CXCL10 in cancers. J Exp Clin Cancer Res 41, 155.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang, Y., Narayanan, S.P., Mannan, R., Raskind, G., Wang, X., Vats, P., Su, F., Hosseini, N., Cao, X., Kumar-Sinha, C., et al. (2021). Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proc Natl Acad Sci USA 118, e2103240118.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhu, Z., Zhang, Y., Wang, H., Jiang, T., Zhang, M., Zhang, Y., Su, B., and Tian, Y. (2022). Renal cell carcinoma associated with HIV/AIDS: a review of the epidemiology, risk factors, diagnosis, and treatment. Front Oncol 12, 872438.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This work was supported by the High-Level Public Health Specialized Talents Project of Beijing Municipal Health Commission (2022-2-018), the National Natural Science Foundation of China (81974303), the “Climbing the peak (Dengfeng)” Talent Training Program of Beijing Hospitals Authority (DFL20191701), and Beijing Key Laboratory for HIV/AIDS Research (BZ0089).

Author information

Author notes

  1. Contributed equally to this work

Authors and Affiliations

  1. Beijing Key Laboratory for HIV/AIDS Research, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China

    Hu Wang, Yihang Zhang, Taiyi Jiang & Bin Su

  2. Department of Urology, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China

    Zhiqiang Zhu, Mengmeng Zhang & Yu Zhang

  3. Department of Urology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, 310022, China

    Zongping Wang

  4. Experimental Research Center, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer, Chinese Academy of Sciences, Hangzhou, 310022, China

    An Zhao

Authors
  1. Hu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiqiang Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yihang Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Taiyi Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mengmeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Zongping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. An Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Bin Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Yu Zhang, An Zhao or Bin Su.

Additional information

Compliance and ethics

The author(s) declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Zhu, Z., Zhang, Y. et al. New insight into immune checkpoint inhibitors in the treatment of advanced renal cell carcinoma. Sci. China Life Sci. 66, 875–878 (2023). https://doi.org/10.1007/s11427-022-2197-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11427-022-2197-7

Search

Navigation